↓ Skip to main content

Targeting Tumor Perfusion and Oxygenation to Improve the Outcome of Anticancer Therapy1

Overview of attention for article published in Frontiers in Pharmacology, January 2012
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user

Citations

dimensions_citation
84 Dimensions

Readers on

mendeley
128 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Targeting Tumor Perfusion and Oxygenation to Improve the Outcome of Anticancer Therapy1
Published in
Frontiers in Pharmacology, January 2012
DOI 10.3389/fphar.2012.00094
Pubmed ID
Authors

Bénédicte F. Jordan, Pierre Sonveaux

Abstract

Radiotherapy and chemotherapy are widespread clinical modalities for cancer treatment. Among other biological influences, hypoxia is a main factor limiting the efficacy of radiotherapy, primarily because oxygen is involved in the stabilization of the DNA damage caused by ionizing radiations. Radiobiological hypoxia is found in regions of rodent and human tumors with a tissue oxygenation level below 10 mmHg at which tumor cells become increasingly resistant to radiation damage. Since hypoxic tumor cells remain clonogenic, their resistance to the treatment strongly influences the therapeutic outcome of radiotherapy. There is therefore an urgent need to identify adjuvant treatment modalities aimed to increase tumor pO(2) at the time of radiotherapy. Since tumor hypoxia fundamentally results from an imbalance between oxygen delivery by poorly efficient blood vessels and oxygen consumption by tumor cells with high metabolic activities, two promising approaches are those targeting vascular reactivity and tumor cell respiration. This review summarizes the current knowledge about the development and use of tumor-selective vasodilators, inhibitors of tumor cell respiration, and drugs and treatments combining both activities in the context of tumor sensitization to X-ray radiotherapy. Tumor-selective vasodilation may also be used to improve the delivery of circulating anticancer agents to tumors. Imaging tumor perfusion and oxygenation is of importance not only for the development and validation of such combination treatments, but also to determine which patients could benefit from the therapy. Numerous techniques have been developed in the preclinical setting. Hence, this review also briefly describes both magnetic resonance and non-magnetic resonance in vivo methods and compares them in terms of sensitivity, quantitative or semi-quantitative properties, temporal, and spatial resolutions, as well as translational aspects.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 128 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Netherlands 1 <1%
United States 1 <1%
South Africa 1 <1%
Unknown 124 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 20 16%
Student > Master 18 14%
Researcher 13 10%
Student > Bachelor 12 9%
Student > Postgraduate 9 7%
Other 29 23%
Unknown 27 21%
Readers by discipline Count As %
Medicine and Dentistry 31 24%
Biochemistry, Genetics and Molecular Biology 14 11%
Agricultural and Biological Sciences 10 8%
Physics and Astronomy 9 7%
Engineering 9 7%
Other 26 20%
Unknown 29 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 May 2013.
All research outputs
#17,664,289
of 22,708,120 outputs
Outputs from Frontiers in Pharmacology
#6,950
of 15,939 outputs
Outputs of similar age
#190,687
of 244,149 outputs
Outputs of similar age from Frontiers in Pharmacology
#77
of 137 outputs
Altmetric has tracked 22,708,120 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 15,939 research outputs from this source. They receive a mean Attention Score of 4.9. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 244,149 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 137 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.